Gubra (GUBRA) Q2 2026 earnings summary

Executive summary

• Achieved strong execution across an integrated business model, advancing the R&D pipeline and expanding commercial initiatives.

• Launched Gubra Ventures to accelerate innovation and value creation beyond the core pipeline, with new leadership established.

• Advanced key obesity programs: GUB-UCN2 entered Phase 1/2a trials; partnered assets with AbbVie and Boehringer Ingelheim moved to Phase 2.

• Expanded infrastructure, doubling lab capacity to support innovation and growth ambitions.

• Multiple key milestones reached, including new clinical trial initiations and positive data from partnered programs.

Financial highlights

• H1 2026 revenue was DKK 126.3 million, down from DKK 2,492.1 million in H1 2025 due to a large one-time AbbVie deal in the prior year.

• Biotech revenue was DKK 30 million in H1 2026, down from DKK 2.4 billion in H1 2025 due to prior year’s AbbVie upfront payment.

• CRO segment external revenue DKK 96.4 million, up 11% sequentially from H2 2025.

• Group EBIT loss of DKK 122.9 million (H1 2025: gain of DKK 2,252.2 million), reflecting absence of major upfront payments.

• Cash and equivalents at DKK 901.3 million; equity at DKK 1,045.7 million as of June 30, 2026.

Outlook and guidance

• 2026 Biotech revenue guidance remains withdrawn due to milestone timing uncertainty; total costs expected at DKK 330-360 million.

• CRO external revenue expected to grow 0-10% in 2026, with 10% annual growth mid-term.

• CRO EBIT margin guided at 10-15% for 2026.

• Continued investment in R&D, infrastructure, and new therapeutic areas aligned with 2030 strategy.

• Multiple value inflection points anticipated in H2 2026 and H1 2027, including clinical trial data and venture launches.